What Is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from gastric juice protein BPC, primarily studied for tissue repair, tendon healing, gastrointestinal protection, and angiogenesis in preclinical rodent models.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids — with the full sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). The compound is derived from a naturally occurring cytoprotective protein (BPC) found in human gastric juice, first characterised and studied extensively by the research group of Dr. Predrag Sikiric at the University of Zagreb. The "157" designation refers to a partial sequence of this larger protein, isolated for its particularly potent biological activity in preclinical models.
Unlike many synthetic peptides that are designed entirely de novo, BPC-157 has an endogenous counterpart — the full BPC protein — and is therefore considered a body-derived sequence. This has made it a subject of interest in gastroenterology research, where the native protein is believed to contribute to gastric mucosal defence. Research in rodent models has demonstrated that BPC-157 can exert protective effects on the GI tract independently of acid suppression, which distinguishes it mechanistically from proton pump inhibitors and H2 blockers studied in parallel experimental contexts.
Since the early work of Sikiric and colleagues, BPC-157 research has expanded substantially beyond gastrointestinal biology. The compound has been studied in bone, tendon, ligament, muscle, and even neurological tissue injury models, producing a diverse body of preclinical literature. With over 165,000 monthly searches and a keyword difficulty of 18, BPC-157 is one of the most researched peptide compounds in the online scientific community. All BPC-157 available from Rainbow Peptide is supplied strictly For Research Use Only and is not suitable for human administration.
Mechanism of Action
BPC-157 acts through at least five identified pathways: NO-system modulation, FAK-paxillin tendon fibroblast signalling, VEGF-driven angiogenesis, growth hormone receptor upregulation, and EGF-mediated GI mucosal cytoprotection.
- ◆
Nitric Oxide (NO) System Modulation BPC-157's effects appear deeply intertwined with the NO pathway. Research indicates it upregulates endothelial nitric oxide synthase (eNOS) and modulates nitric oxide production in vascular endothelium. The NO system plays critical roles in vasodilation, mucosal blood flow maintenance, and tissue oxygenation — mechanisms relevant to both GI and wound healing research models.
- ◆
FAK-Paxillin Pathway Activation In tendon fibroblast studies, BPC-157 has been shown to activate the focal adhesion kinase (FAK) — paxillin signalling cascade, which regulates cell migration, adhesion, and cytoskeletal organisation. This mechanism is proposed to underlie the compound's observed effects on tendon fibroblast proliferation and migration toward injury sites in in vitro scratch assay models.
- ◆
Angiogenesis Promotion via VEGF Multiple rodent studies report BPC-157 upregulates VEGF expression and promotes neovascularisation in healing tissue. Enhanced angiogenic response in wound healing and tendon repair models correlates with accelerated functional recovery scores. This pro-angiogenic effect is considered a key mechanism in the compound's broad tissue recovery research profile.
- ◆
Growth Hormone Receptor Upregulation Unusually for a peptide of its size, BPC-157 appears to modulate growth hormone receptor (GHR) expression. Research has proposed this as a mechanism through which BPC-157 may amplify GH signalling in damaged tissue — potentially contributing to increased IGF-1 expression locally at wound sites in experimental models.
- ◆
GI Mucosal Cytoprotection In gastric injury models (NSAID-induced ulceration, alcohol-induced damage, surgical anastomosis), BPC-157 has demonstrated consistent cytoprotective activity. Proposed mechanisms include upregulation of EGF receptor expression on mucosal cells, stimulation of mucus secretion, and reduction of inflammatory cytokine expression in gastric tissue.
Reconstitution Reference
The following reference is provided for licensed research professionals only. All reconstitution and handling must comply with your institution's biosafety protocols.
| Vial Size | BAC Water Volume | Resulting Concentration | Typical Research Dose Range | Peptide Calculator |
| 5 mg | 2.0 mL | 2,500 mcg/mL | 200 – 500 mcg | Calculate Dose → |
| 10 mg | 4.0 mL | 2,500 mcg/mL | 200 – 500 mcg | Calculate Dose → |
Bacteriostatic water is the standard diluent. Inject BAC water slowly along the vial wall — do not shake; gently swirl to dissolve. Store reconstituted BPC-157 at 2–8°C and use within 28 days. Lyophilised powder is stable at -20°C for up to 24 months.
Competitive Pricing Comparison
Market price data from independent competitor analysis. All products are For Research Use Only.
| Supplier | Price Range (per vial) | Avg Market Price | COA Available |
| Competitor Low | $52 | — | Varies |
| Competitor High | $119 | — | Varies |
| Market Average | — | $78 | — |
| Rainbow Peptide | View Price → | ✓ Yes — HPLC + MS |
Published Research References
Studies cited for scientific reference only. All data from preclinical rodent models unless stated. This is not medical advice.
- Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857–865. PubMed 27600467 ↗
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774–780. PubMed 21159593 ↗
- Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL14736)." Curr Pharm Des. 2011;17(16):1612–1632. PubMed 21864258 ↗
- Sikiric P, et al. "Cytoprotection and injury alleviation: From alcohol lesions to NSAID side effects to organ damage." J Physiol Pharmacol. 2020;71(5). PubMed 33811787 ↗